173 Ces Urol 2022; 26(3): 165–173 PŘEHLEDOVÉ ČLÁNKY 5. Kobayashi H, Carrasquillo JA, Paik CH, Waldmann TA, Tagaya Y. Differences of biodistribution, phar‑ macokinetics, and tumor targeting between interleukins 2 and 15 Cancer Res 2000; 60(13): 3577–83 6. ImmunityBio. 14 2 2022, ImmunityBio Announces Over 24 Months Median Duration of Complete Re‑ mission, with 100% NMIBC CIS Patient Survival, Setting a New ‘Magnitude of Benefit’ in Patients with BCG Unresponsive Bladder Cancer (online) Dostupné z: https://immunitybio com/immunitybio‑announces ‑over-24-months‑median‑duration‑of‑complete‑remission‑with-100-%NBIMC‑CIS 7. Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD‑L1 Checkpoint Signaling Inhibition for Cancer Im‑ munotherapy: Mechanism, Combinations, and Clinical Outcome Frontiers in pharmacology 2017; 8: 561 8. Kumar V, Chaudhary N, Garg M, et al. Corrigendum: Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy Frontiers in pharmaco‑ logy 2017; 8: 311 9. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade Science 2017; 357(6349): 409–13 10. Thana M, Wood L. Immune checkpoint inhibitors in genitourinary malignancies Current onkology 2020; 27(Suppl 2): S69–S77 11. Mondal M, Guo J, He P, et al. Recent advances of oncolytic virus in cancer therapy Human vacci‑ nes & immunotherapeutics 2020; 16(10): 2389–402 12. Razzaghdoust A, Rahmatizadeh S, Mofid B, et al. Data‑Driven Discovery of Molecular Targets for Antibody‑Drug Conjugates in Cancer Treatment BioMed research international 2021; 2021: 2670573 13. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer Science 2015; 348(6230): 62–8 14. Perera MPJ, Thomas PB, Risbridger GP, et al. Chimeric Antigen Receptor T‑Cell Therapy in Metastatic Castrate‑Resistant Prostate Cancer Cancers 2022; 14(3) 15. Madan RA, Antonarakis ES, Drake CG, et al. Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel‑T Journal of the National Cancer Institute 2020; 112(6): 562–73 16. Vogelzang NJ, Beer TM, Gerritsen W, et al. Efficacy and Safety of Autologous Dendritic Cell‑Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration‑Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial JAMA onkology 2022 17. Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for Metastatic Castration‑Resistant Prostate Cancer The New England journal of medicine 2021; 385(12): 1091–103 18. Schulz GB, Black PC. Combination therapies involving checkpoint‑inhibitors for treatment of urothelial carcinoma: a narrative review Translational andrology and urology 2021; 10(10): 4014–21 19. Kwon WA, Seo HK. Emerging agents for the treatment of metastatic urothelial cancer Investigative and clinical urology 2021; 62(3): 243–55 20. Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma The New England journal of medicine 2021; 384(12): 1125–35 21. Bansal A, Singh J, Kaur S, Kaur N. Enfortumab Vedotin‑Induced Toxic Epidermal Necrolysis: A Rare Fatal Adverse Reaction Indian dermatology online journal 2022; 13(1): 128–30 22. Schmidinger M, Resch I, Fajkovic H, et al. Dual immune check point blockade or immune check point‑tyrosine kinase inhibitor combination: as a first‑line treatment in metastatic renal cell carcinoma? Current opinion in urology 2021; 31(3): 270–5
RkJQdWJsaXNoZXIy NDA4Mjc=